undamentalytics Newsletter
Sign in

Quidelortho Corp income statement

In fiscal 2025, Quidelortho Corp reported revenue of $2.73bn, down 1.9% on the year before, operating income of −$919m (a -33.7% margin) and net income of −$1.13bn, or −$16.69 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Jan 20212021Jan 20222022Jan 20232023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,6621,6993,2662,9982,7832,7302,674
Research and development8496188245219186181
Selling, general and administrative181240621763767746770
Operating income1,060906844139−1,961−919−825
Interest expense——76148164178203
Net interest income−9−6−76−148−164——
Income before tax1,040900736−29−2,132−1,108−1,030
Income tax230196187−19−802418
Net income810704549−10−2,052−1,132−1,048
Diluted EPS$18.60$16.43$9.56−$0.15−$30.54−$16.69−$15.39
Diluted shares (average)44m43m57m67m67m68m68m
EBITDA1,1099591,127596−1,508−477−371

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: QDEL vs RVTYPODD vs QDELENOV vs QDELGMED vs QDEL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Quidelortho Corp's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Quidelortho Corp.